Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

被引：6
作者：
Daniel Aletaha
Josef S. Smolen
机构：
[1] Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna
来源：
Current Rheumatology Reports | 2003年 / 5卷 / 6期
关键词：
Rheumatoid Arthritis; Leflunomide; Anakinra; Drug Survival; High Disease Activity;
D O I：
10.1007/s11926-003-0048-y
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：409 / 412
页数：3
相关论文
共 9 条
  • [1] Wolfe F(1999)Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology J Rheumatol 26 484-489
  • [2] Lassere M(1999)Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies Ann Rheum Dis 58 I82-I85
  • [3] van der HD G(1990)Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy J Rheumatol 22 12-15
  • [4] Stucki C(2002)The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses Rheumatology (Oxford) 41 1367-1374
  • [5] Bombardier A(undefined)undefined undefined undefined undefined-undefined
  • [6] Maetzel JF(undefined)undefined undefined undefined undefined-undefined
  • [7] Fries D(undefined)undefined undefined undefined undefined-undefined
  • [8] Aletaha JS(undefined)undefined undefined undefined undefined-undefined
  • [9] Smolen undefined(undefined)undefined undefined undefined undefined-undefined
1